http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 윤성도(Sung-Do Young) (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
권지윤,윤성도,조동현,길영식,김수경,Kwon, Gee-Youn,Yoon, Sung-Do,Cho, Dong-Hyun,Gil, Young-Sig,Kim, Soo-Kyung 대한임상약리학회 2003 Translational and Clinical Pharmacology Vol.11 No.2
Background: This study was conducted to evaluate the bioavailability of Fluconazole formulation in healthy Korean volunteers. Furthermore, the bioequivalence of $Flukan^{\circledR}$ capsule, a fluconazole preparation from Korea United Pharm, Inc., was determined. Methods: The study employed a randomized, two-way crossover Latin square design with a two-week washout period. The test product was $Flukan^{\circledR}$ capsule (Korea United Pharm Inc., South Korea) and the reference was $Diflucan^{\circledR}$ capsule (Pfizer Inc.). The two products were administered in 150 mg single oral doses into 26 healthy Korean volunteers. Serial blood samples were collected for a period of 120 hours. Plasma fluconazole concentrations of the two brands were measured by HPLC using UV detector, and the pharmacokinetic parameters including $AUC_t,\;C_{max},\;T_{max}$, and half-life were determined from plasma concentrations of both formulations. Results: Both formulations were well tolerated in 26 volunteers. Mean $AUC_t,\;C_{max}$ of $Flukan^{\circledR}$ capsule were 1.068 $(90%\;confidence\;interval:\;1.0057{\leq\delta\leq}1.1349)$ and 1.017 $(90%\;confidence\;interval:\;0.9633{\leq\delta\leq}1.0749)$ compared to those of $Diflucan^{\circledR}$ capsule. Mean half-life of $Flukan^{\circledR}$ capsule was $30.41{\pm}5.44$ and that of $Diflucan^{\circledR}$ capsule was $30.74{\pm}5.86$ hr. The powers $(1-{\beta})$ for $AUC_t\;and\;C_{max}$ were above 90%. The pharmacokinetic parameters $(AUC_t,\;C_{max},\;T_{ max})$ were analyzed statistically with K-BE test 2002 (KFDA). Conclusion : No significant differences between two formulations were observed in terms of $AUC_t\;and\;C_{max}$, the main pharmacokinetic parameters used for bioequivalence evaluation. The results satisfied the bioequivalence criteria of KFDA guidelines, and $Flukan^{\circledR}$ capsule was determined to be bioequivalent to $Diflucan^{\circledR}$ capsule.
-
Resveratrol에 의한 자궁근종세포의 성장억제 효과
강보영 ( Bo Young Kang ),조치흠 ( Chi Heum Cho ),김숙현 ( Sook Hyun Kim ),신소진 ( So Jin Shin ),권상훈 ( Sang Hoon Kwon ),박준철 ( Joon Cheol Park ),이정호 ( Jeong Ho Rhee ),김종인 ( Jong In Kim ),차순도 ( Soon Do Cha ),윤성도 ( 대한산부인과학회 2006 Obstetrics & Gynecology Science Vol.49 No.12
Objective: To examine the effect of resveratrol on cell proliferation and cell cycle progression in the human uterine leiomyoma cells. Methods: MTS [3-(4,5-dimethylthiazol-2-yl)5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] reduction assay was carried out to determine the viability of human uterine leiomyoma cells. Western blot analysis was done using anti pRB, anti- p21cip1/waf1, anti- p53, anti- cyclin E, anti CDK2 antibodies to detect the presence and expression of these proteins in treatment with resveratrol. DNA fragmentation assay was done to find the rate of apoptosis. Cell cycle analysis for resveratrol treated in human uterine leiomyoma cells was done by FACS (fluorescence-activated cell sorter) analysis. Results: Resveratrol induced growth inhibition in a dose dependent manner, treatment with 100 μM/L resveratrol blocked 30% cell growth. From Western blot analysis it revealed resveratrol induced the expression of p53 increasing. Caspase pathway was activated and cleavage of PARP was occurred. Apoptosis took place but in a reduced manner. FACS results showed that resveratrol increased the percentage of cells in sub G1 phase. Conclusion: Resveratrol, a dietry phytoalexin, inhibited cell proliferation and induced cell cycle arrest at sub G1 by enhancing the production of p53. These results indicate that resveratrol will be a promising agent chemopreventives or therapeutics against human uterine leiomyoma cells.
-
서장수(Jang-Soo Suh),홍재희(Jai-Hee Hong),윤성도(Sung-Do Young),노희숙(Hee-Sook Noh),양동철(Dong-Cheol Yang),양일신(Il-Shin Yang),전정현(Jung-Hyun Jun),김재국(Jae-Kook Kim) 대한전기학회 2012 대한전기학회 학술대회 논문집 Vol.2012 No.10
리튬이차전지용 양극소재를 제조하는 다양한 공정들의 단점을 개선시키기 위하여 본 연구에서는 분무 열 합성법을 연구하였다. 분무 열 합성법은 화염내의 화학적 활성이 높은 열에너지를 이용하여 분체를 제조하는 기술이다. 본 기술로서 얻어지는 분체는 표면장력에 의해 구형의 나노입자를 얻을 수 있다. 또한, 기존의 제조공정에 비하여 공정이 간단하고 미립자 조절, 산화와 환원, 표면개짙 등이 동시에 이루어진다는 장점을 가지고 있다. 또한 본 기술은 다른 양극소재와 음극소재, 세라믹 제조에도 폭 넓게 응용될 수 있을 것으로 기대된다.
KISS연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
